A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. 1986

L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen

Twelve patients with neuroleptic-induced akathisia were treated in a randomised, double-blind, cross-over design with propranolol and matching placebo. Propranolol caused significant decrements in both subjective and objective ratings of akathisia, but not in anxiety scores. This confirms prior findings of the efficacy of propranolol in akathisia induced by neuroleptic treatment.

UI MeSH Term Description Entries
D008297 Male Males
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011595 Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions. Agitation, Psychomotor,Akathisia,Excitement, Psychomotor,Restlessness,Psychomotor Hyperactivity,Psychomotor Restlessness,Hyperactivity, Psychomotor,Psychomotor Excitement,Restlessness, Psychomotor
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
January 2005, Primary care companion to the Journal of clinical psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
January 1989, The Hillside journal of clinical psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
March 1984, The American journal of psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
October 1988, Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
September 1983, Lancet (London, England),
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
January 1988, The Hillside journal of clinical psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
November 1988, Biological psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
June 1987, The American journal of psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
May 1992, The American journal of psychiatry,
L Adler, and B Angrist, and E Peselow, and J Corwin, and R Maslansky, and J Rotrosen
August 1993, Clinical neuropharmacology,
Copied contents to your clipboard!